A new vaccine on the horizon. Surprisingly effective against severe COVID-19
Start COVID-19 vaccine Frequently asked questions Where can I get vaccinated? Check if you can get vaccinated

Another may soon join the arsenal of vaccines against COVID-19. This time based on traditional protein technology. The French-British Sanofi-GSK has just announced the results of the final phase of clinical trials. The level of protection against “severe course and hospitalization was unrivaled”. How does Sanofi-GSK work, and what else has the studies shown? Get to know the details.

  1. Franco-British Sanofi-GSK has announced the results of the third phase of clinical trials on a new vaccine against COVID-19, the company is seeking approval for the US and European markets
  2. Sanofi-GSK vaccine contains a modified harmless version of the coronavirus spike protein that allows the body to build up immunity
  3. After the administration of two doses, the vaccine was observed that the preparation was: 58 percent. effective in preventing COVID-19 symptoms, in 75 percent effective in preventing moderate COVID-19, 100% effective against severe infection, including hospitalization
  4. The formulation was also tested as a booster dose. As it turned out?
  5. Check your health. Just answer these questions
  6. More information can be found on the Onet homepage

A more traditional COVID-19 vaccine. How it works?

The COVID-19 pandemic is not over yet. Anyone who can, should get vaccinated – doctors invariably remind them. Another one may soon be added to the set of currently used preparations. It is a two-dose preparation created by the French-British Sanofi-GSK concern, which has just announced the results of the last phase of clinical trials. “We are very pleased with the figures,” said Sanofi Executive Vice President Thomas Triomphe.

Before presenting the results of clinical trials, it is worth explaining how Sanofi-GSK works. This could be important for people who still have not opted for the COVID-19 vaccine. Sanofi-GSK is a more traditional type of vaccine than mRNA or vector preparations. As with other COVID-19 vaccines, Sanofi-GSK also targets the SARS-CoV-2 spike protein, which allows the virus to infect cells.

Further part below the video.

However, while mRNA vaccines work by providing our cells with the information they need to make this protein (and this helps the immune system learn how to recognize and fight it), Sanofi-GSK contains a modified, harmless version of it.

  1. Moderna’s deputy head: we must be ready that a new variant of the coronavirus will appear in the fall

These types of vaccines do not need to be stored at very low temperatures, a simple refrigerator will suffice.

New COVID-19 vaccine. What happens after two doses?

The trials of the third phase of clinical trials began in May 2021. Over 10 people took part. adults from the United States, Asia, Africa and Latin America. They concerned the effectiveness of the primary vaccination course (a separate study assessed the protection of the preparation as a booster dose).

  1. What gives better immunity – vaccine or disease? A new discovery

Although it turned out that the vaccine prevents the symptoms of COVID-19 only in 58%, the level of protection against the severe form of the disease, and therefore hospitalization, is unrivaled at 100%. And when it comes to preventing moderate COVID-19, the vaccine was 75 percent effective.

Do you want to test your COVID-19 immunity after vaccination? Have you been infected and want to check your antibody levels? See the COVID-19 immunity test package, which you will perform at Diagnostics network points.

It is worth noting that, unlike mRNA preparations, the new vaccine was tested in the presence of new SARS-CoV-2 variants. “During this period, no other global Phase XNUMX efficacy study has been conducted with so many worrying variants, including Omikron, and these efficacy data are similar to recent clinical data from approved vaccines,” said Thomas Triomphe.

  1. Sub-variant BA.2 of the Omicron worries more and more. Is he as dangerous as Delta?

New COVID-19 vaccine as a booster

Sanofi-GSK also said the vaccine worked well as a booster, including as a mix-and-match booster. The manufacturers note that the tests did not identify any safety problems.

When the preparation was administered to people who had previously received the Pfizer, Moderna, J&J or AstraZeneki vaccines, the level of neutralizing antibodies increased 18 to 30 times. For participants whose initial vaccination schedule was Sanofi-GSK, the increase was 84-153-fold.

This is important information because, as the company’s spokesman points out, the most likely role for the vaccine in the US and European market (where many people have completed the primary vaccination course) will be a booster vaccination.

As announced by the company, full data and research results are to be published this year.

At the same time, we encourage you to listen to the latest episode of the RESET podcast. This time we were talking about breathing. Breathe with your mouth or nose? How To Get Rid Of Bad Breathing Habits? What is breath re-reduction and how does it affect our mental and physical health? You will hear about this and many other aspects of breathing below.

You may be interested in:

  1. Infection with two Omicron sub-variants is possible. What is the threat of this?
  2. Can you have long covid after Omikron? Here are the disturbing symptoms
  3. Fourth dose for everyone? Clear position of the European Medicines Agency

Leave a Reply